Won't be 'same ole, same ole' for ODAC at Perjeta meeting
This article was originally published in Scrip
Executive Summary
When the FDA's Oncologic Drugs Advisory Committee (ODAC) meets on 12 September to review the supplemental biologics license application (sBLA) for Genentech's Perjeta (pertuzumab), a humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER2 tyrosine kinase receptor, the panel will have some new topics of discussion on the table.